Ercros SA (ES:ECR)
BME:ECR
Top Page
Ercros SA
(BME:ECR)
Select Model
Select Model
Rating:40Underperform
Price Target:
€3.00
▼(-12.54% Downside)
Action:DowngradedDate:03/03/26
Ercros SA receives a low score primarily due to fundamental deterioration, evidenced by widening losses, margin compression, and increasing leverage. Valuation is a major drag given the lack of profitability. While technical indicators show the stock holding long-term support and positive cash flow exists, the prevailing negative trend and poor income profile dominate the rating.
Positive Factors
Diversified end-markets
Ercros sells chlorine/caustic and active pharmaceutical ingredients across varied industries. This product and end-market diversity supports revenue resilience over cycles, allowing the company to shift focus between industrial and pharma demand and reduce single-market dependence.
Negative Factors
Deteriorating profitability
A sustained swing into losses erodes retained earnings, restricts reinvestment and weakens competitiveness. Persistent negative operating profit reduces ability to fund R&D, maintenance and strategic initiatives, making recovery more difficult and increasing reliance on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified end-markets
Ercros sells chlorine/caustic and active pharmaceutical ingredients across varied industries. This product and end-market diversity supports revenue resilience over cycles, allowing the company to shift focus between industrial and pharma demand and reduce single-market dependence.
Read all positive factors
Ercros SA (ECR) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€312.25M
Dividend Yield2.27%
Average Volume (3M)68.83K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue Growth-0.39%
EPS Growth-440.04%
CountryES
Employees1,318
SectorGeneral
Sector StrengthN/A
IndustryChemicals
Share Statistics
EPS (TTM)N/A
Shares Outstanding91,436,195
10 Day Avg. Volume92,838
30 Day Avg. Volume68,826
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)0.50
P/FCF Ratio15.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ercros SA Business Overview & Revenue Model
Company Description
Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces am...
How the Company Makes Money
Ercros generates revenue through the production and sale of its chemical products, with significant income derived from the Chlor-Alkali segment, particularly chlorine and caustic soda, which are used in numerous industrial applications. The Pharm...
Ercros SA Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
42
Neutral
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 626.82M | 667.41M | 725.29M | 998.53M | 772.32M |
| Gross Profit | 58.99M | 200.63M | 230.62M | 305.94M | 246.80M |
| EBITDA | 6.25M | 25.91M | 43.27M | 121.71M | 90.85M |
| Net Income | -53.59M | -11.66M | 27.59M | 62.99M | 43.30M |
Balance Sheet | |||||
| Total Assets | 694.30M | 699.19M | 683.32M | 746.55M | 709.96M |
| Cash, Cash Equivalents and Short-Term Investments | 96.03M | 31.49M | 39.15M | 55.48M | 50.30M |
| Total Debt | 223.06M | 172.34M | 131.25M | 135.43M | 120.00M |
| Total Liabilities | 396.07M | 358.03M | 320.20M | 385.84M | 378.34M |
| Stockholders Equity | 287.25M | 341.16M | 363.12M | 360.71M | 331.61M |
Cash Flow | |||||
| Free Cash Flow | 20.04M | -4.04M | 17.30M | 35.80M | 47.42M |
| Operating Cash Flow | 49.19M | 9.51M | 51.14M | 62.99M | 60.32M |
| Investing Cash Flow | -29.15M | -26.67M | -33.84M | -52.81M | -34.24M |
| Financing Cash Flow | 40.04M | 14.33M | -35.91M | -21.45M | -14.68M |
Ercros SA Technical Analysis
Positive
3.43
Price Trends
3.37
Positive
3.35
Positive
3.09
Positive
Market Momentum
0.03
Negative
54.49
Neutral
10.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ECR, the sentiment is Positive. The current price of 3.43 is above the 20-day moving average (MA) of 3.38, above the 50-day MA of 3.37, and above the 200-day MA of 3.09, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.49 is Neutral, neither overbought nor oversold. The STOCH value of 10.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:ECR.
Ercros SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €4.18B | 23.13 | 23.03% | 1.50% | -9.39% | -25.92% | |
64 Neutral | €26.56B | 9.83 | 7.85% | 6.18% | -6.61% | -44.09% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €5.71B | 18.75 | 7.56% | 1.37% | 7.31% | 158.58% | |
51 Neutral | €1.46B | 20.17 | 18.13% | 3.51% | 11.04% | 8.29% | |
46 Neutral | €202.54M | 41.66 | 2.03% | 1.91% | -1.19% | -54.66% | |
40 Underperform | €312.25M | -5.85 | -20.66% | 2.27% | -0.39% | -440.04% |
* General Sector Average
ES:ECR
Ercros SA
3.42
0.69
25.09%
ES:FAE
Faes Farma
4.70
1.10
30.42%
ES:GRF
Grifols
9.20
1.46
18.88%
ES:RJF
LABORATORIO REIG JOFRE
2.48
-0.06
-2.21%
ES:ROVI
Laboratorios Farmaceuticos Rovi
82.65
36.29
78.28%
ES:REP
Repsol
24.27
14.78
155.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.